Cara Therapeutics Company Profile (NASDAQ:CARA)

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics Inc (NASDAQ:CARA) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.08. The firm earned $0.91 million during the quarter, compared to the consensus estimate of $0.11 million. The business's quarterly revenue was up 12900.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) EPS. View Cara Therapeutics' Earnings History.

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Cara Therapeutics.

11 analysts have issued 12 month price objectives for Cara Therapeutics' stock. Their forecasts range from $22.00 to $35.00. On average, they expect Cara Therapeutics' stock price to reach $28.08 in the next year. View Analyst Ratings for Cara Therapeutics.

Here are some recent quotes from research analysts about Cara Therapeutics stock:

• 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (5/10/2017)
• 2. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
• 3. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
• 4. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)
• 5. Needham & Company LLC analysts commented, "Cara announced positive results from Phase 2/3 trial of IV CR845 in Uremic Pruritus (Itch associated w/ Hemodialysis pts). Part A of trial met both primary endpt in itch reduction and secondary endpt in Skindex-10 quality of life. Effect size increased relative to placebo over time and we believe findings are clinically meaningful. Safety/ tolerability of lower two doses appears acceptable. End of Phase 2 mtg planned and mgmt guided for initiation 12wk Phase 3 trial (Part B) by YE17. A 2nd Phase 3 trial may be needed, subject to FDA. Cara also plans to initiate open-label 12mo Phase 3 trial in 3Q17." (3/28/2017)

Cara Therapeutics saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 5,942,697 shares, an increase of 19.8% from the March 31st total of 4,962,108 shares. Based on an average daily volume of 2,606,962 shares, the days-to-cover ratio is currently 2.3 days.

Some companies that are related to Cara Therapeutics include Coherus Biosciences (CHRS), Insys Therapeutics (INSY), Insmed Incorporated (INSM), Xencor (XNCR), Acceleron Pharma (XLRN), Forward Pharma A/S (FWP), Epizyme (EPZM), Aimmune Therapeutics (AIMT), Cellectis SA (CLLS), Immunomedics (IMMU), ZIOPHARM Oncology (ZIOP), Alder Biopharmaceuticals (ALDR), Five Prime Therapeutics (FPRX), Ascendis Pharma A/S (ASND), Albany Molecular Research (AMRI), Achaogen (AKAO), TG Therapeutics (TGTX) and Esperion Therapeutics (ESPR).

Cara Therapeutics' management team includes the folowing people:

• Derek T. Chalmers Ph.D., President, Chief Executive Officer, Director
• Josef C. Schoell CPA, Chief Financial Officer
• Frederique Menzaghi Ph.D., Vice President, Research & Development
• Joseph William Stauffer, Chief Medical Officer
• Harrison M. Bains Jr., Independent Director
• Jeffrey L. Ives Ph.D., Independent Director
• Dean Slagel, Independent Director
• Martin A. Vogelbaum, Independent Director

Cara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RHO Capital Partners Inc. (13.07%), Vanguard Group Inc. (3.46%), FMR LLC (3.44%), Chescapmanager LLC (3.27%), JPMorgan Chase & Co. (1.27%) and Morgan Stanley (1.22%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Josef Schoell, Michael E Lewis and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Janney Montgomery Scott LLC, Ameriprise Financial Inc., Dimensional Fund Advisors LP, JPMorgan Chase & Co., Goldman Sachs Group Inc., Baldwin Brothers Inc. MA and EAM Investors LLC. View Insider Buying and Selling for Cara Therapeutics.

Cara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, RHO Capital Partners Inc., Jennison Associates LLC, UBS Asset Management Americas Inc., Morgan Stanley, Chescapmanager LLC, Vanguard Group Inc. and Monashee Investment Management LLC. Company insiders that have bought Cara Therapeutics stock in the last two years include Josef Schoell and Ventures Vi Lp Rho. View Insider Buying and Selling for Cara Therapeutics.

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cara Therapeutics stock can currently be purchased for approximately $16.71.